Head and Neck Squamous Cell Carcinoma, Lung Non-Small Cell Carcinoma, Stage I Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage II Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
Conditions
Brief summary
This clinical trial investigates the acceptability of electronic cigarettes (JUUL) for smoking cessation (quitting smoking) and the reduction of surgery-related complications in patients with newly diagnosed head, neck, or lung cancer. Smoking before surgery is associated with increased risk of complications during and after surgery. Electronic cigarettes are a type of special product that gives small, steady doses of nicotine to help stop cravings and relieve symptoms that occur when a person is trying to quit smoking. Stopping cigarette smoking before surgery may reduce the risk of complications during and after surgery in patients with head, neck, or lung cancer.
Detailed description
PRIMARY OBJECTIVES: I. To evaluate feasibility, acceptability, compliance, and safety of a non-randomized 2-month trial of a pod based electronic cigarette (intervention) versus usual care for stage I-III lung cancer patients and stage I-IV head and neck cancer patients undergoing surgical resection. II. Examine the effect of the pod based electronic cigarette (intervention) on surgical complications, quality of life, and whether it promotes complete or incomplete switching to the non-combustible product. OUTLINE: Patients choose to participate in 1 of 2 arms. ARM I: Beginning 1 month before surgery, patients receive a JUUL e-cigarette and a 1 month supply e-liquid pods. After completion of surgery, patients receive another 1 month supply of e-liquid pods. ARM II: Patients receive usual care. After completion of study intervention, patients are followed up at 2 and 6 months.
Interventions
OTHERBest Practice
Given usual care
Given JUUL
OTHERQuality-of-Life Assessment
Ancillary studies
OTHERQuestionnaire Administration
Ancillary studies
Sponsors
National Cancer Institute (NCI)
Ohio State University Comprehensive Cancer Center
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Newly diagnosed lung cancer subjects will be stages I-III non-small cell lung cancer (NSCLC) and head and neck cancer subjects will be stages I-IV squamous cell carcinoma (SCC). * Current smokers of combustible cigarettes who smoke \>= 4 days/week. * Lung cancer patients planning to undergo wedge resection surgery for their index cancer. * Head and neck cancer patients planning to undergo surgical resection of their index cancer or exploratory biopsies (tonsil cancer). * Patients must intend to receive ongoing oncology care at Ohio State University \[OSU\] (i.e., their clinic visit is not a consultation/second opinion). * Patients that are over the age of 21 years.
Exclusion criteria
* Patients who are cognitively unable to understand the consent form or participate in interviews. * Patients with hearing impairments. * Patients who are planning to use or are currently using cessation medication to help quit or reduce smoking. * Patients who are currently using e-cigarettes. * Patients undergoing surgery including lobectomy, pneumonectomy, tracheotomy, laryngectomy, or free flap surgery. * Patients with contraindications to per oral intake. * Lung cancer patients who are on home supplemental oxygen at baseline. * Patients that have problems with dexterity that would impact electronic cigarette use. * Patients under 21 years of age. * Patients who don't speak and read English. * Patients with histologies other than NSCLC, or squamous cell carcinoma of the head and neck. * Patients with nasopharyngeal, thyroid, or gland cancers. * Patients with inoperable tumors. * Pregnant women. * Prisoners.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Feasibility of patients measured by number of screened per month | Up to 6 months | Will be measured by the number of screened patients per month. |
| Feasibility of patients measured by number of screened per month by eligibility status | Up to 6 months | Will be measured by the number of screened patients per month by eligibility status. |
| Feasibility of patients measured by number of screened per month by refusal status | Up to 6 months | Will be measured by the number of screened patients per month by refusal status. |
| Reasons for participant ineligibility | Baseline | We will record reasons for patient ineligibility |
| Reasons for participant refusal | Baseline | We will record reasons for patient refusal to participate |
| Acceptance measured by participation rate | Up to 6 months | Will be measured by the participation rate, the number of eligible participants who consent and agree to study participation. |
| Compliance | Up to 6 months | Will be self-reported and include counting of used JUUL pods on follow-ups interviews. |
| Adherence | Baseline and hospital admission for surgery | Further, exhaled carbon monoxide (a marker of short-term smoking status) will be assessed at baseline and upon hospital admission for surgery. |
| Incidence of adverse events (AEs) | Up to 14 days after delivery of intervention | Will be assessed at days 2 and 14 following the delivery of the intervention and reported by participants. Further, participants will be invited to contact the research team to report any adverse events related to the use of the intervention at any time point. |
| Complication rate (primary preliminary efficacy) | Up to 6 months | Will be measured as the number of complications reported, per person month of follow up. |
| Quality of life (QOL) - anxiety & depression | Up to 6 months | Self-reported QOL measures will include the GAD-7 (anxiety and depressive symptoms) |
| Quality of life (QOL) - anxiety & depression 2 | Up to 6 months | Self-reported QOL measures will include the PHQ-9 (anxiety and depressive symptoms) |
| Quality of life (QOL) - Perceptions of cancer | Up to 6 months | Self-reported QOL measures will include the Perceptions of Lung Cancer to assess views on their disease (modified slightly for head and neck cancer patients) |
| Quality of life (QOL) - Health outcomes | Up to 6 months | Self-reported QOL measures will include the EQ-5D-5L to assess overall and cancer-specific health outcomes (including cough, dyspnea, dysphagia, and pain). |
| Quality of life (QOL) - Health outcomes 2 | Up to 6 months | Self-reported QOL measures will include the and EORTC-QLQ-LC13 to assess overall and cancer-specific health outcomes (including cough, dyspnes, dysphagia, and pain). |
| 7 day point prevalence of tobacco use | Up to 6 months | 7-day point prevalence of tobacco use (i.e., switching) will be measured at follow-ups |
Countries
United States
Outcome results
None listed